How do UCH-mediated ubiquitination imbalances differentially drive cancer versus neurodegeneration?

While both diseases show ubiquitination/deubiquitination imbalances involving UCHs, the specific mechanisms determining whether cells become malignant or degenerate remain unclear. This knowledge gap limits targeted therapeutic development for either condition.

Gap type: unexplained_observation Source paper: Ubiquitin Carboxyl-Terminal Hydrolases (UCHs): Potential Mediators for Cancer and Neurodegeneration. (None, None, PMID:32486284)

[“Ubiquitin profiling (Ubiquitin\u6b8b\u57fa profiling) in cancer vs neurodegeneration cell models identifies 8-12 substrate specificity differences for UCH family members”, “UCH-L1 and UCH-L3 knockout in neuronal cells causes accumulation of polyubiquitin chains with K63 linkage vs K48 linkage in cancer cells”, “Systematic mutation of UCH active site residues switches cellular phenotype between neurodegeneration-like and cancer-like states”, “Patient tissue analysis (n>=30 each) shows distinct UCH phosphorylation patterns differentiating cancer from neurodegenerative disease”]